Does the media favor HLS or CPH?

In the previous week, HLS Therapeutics had 1 more articles in the media than Cipher Pharmaceuticals. MarketBeat recorded 3 mentions for HLS Therapeutics and 2 mentions for Cipher Pharmaceuticals. Cipher Pharmaceuticals' average media sentiment score of 1.23 beat HLS Therapeutics' score of 0.51 indicating that Cipher Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HLS Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cipher Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer HLS or VGW?

HLS Therapeutics presently has a consensus target price of C$6.00, suggesting a potential upside of 50.38%. Given HLS Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe HLS Therapeutics is more favorable than Valens GroWorks. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HLS Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Valens GroWorks 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer HLS or VBV?

HLS Therapeutics currently has a consensus target price of C$6.00, suggesting a potential upside of 50.38%. Given HLS Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe HLS Therapeutics is more favorable than VBI Vaccines. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HLS Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 VBI Vaccines 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, HLS or VBV?

HLS Therapeutics has higher revenue and earnings than VBI Vaccines. HLS Therapeutics is trading at a lower price-to-earnings ratio than VBI Vaccines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HLS Therapeutics C$55.74M 2.24 -C$15.53M -C$0.32 N/A VBI Vaccines C$3.36M 0.00 -C$62.16M -C$0.97 N/A

Do analysts prefer HLS or FIRE?

HLS Therapeutics currently has a consensus price target of C$6.00, suggesting a potential upside of 50.38%. Given HLS Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe HLS Therapeutics is more favorable than Supreme Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HLS Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Supreme Cannabis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media refer more to ACB or HLS?

In the previous week, Aurora Cannabis had 1 more articles in the media than HLS Therapeutics. MarketBeat recorded 4 mentions for Aurora Cannabis and 3 mentions for HLS Therapeutics. Aurora Cannabis' average media sentiment score of 0.77 beat HLS Therapeutics' score of 0.51 indicating that Aurora Cannabis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurora Cannabis 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HLS Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

HLS Therapeutics (HLS) Competitors

C$3.91 +0.04 (+1.03%)

As of 01:33 PM Eastern

Compare

HLS vs. CPH, VGW, VBV, FIRE, and ACB

Should you buy HLS Therapeutics stock or one of its competitors? HLS Therapeutics's main competitors and comparable companies include Cipher Pharmaceuticals (CPH), Valens GroWorks (VGW), VBI Vaccines (VBV), Supreme Cannabis (FIRE), and Aurora Cannabis (ACB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does HLS Therapeutics compare to Cipher Pharmaceuticals?

HLS Therapeutics (TSE:HLS) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

HLS Therapeutics has a beta of -0.178651, indicating that its share price is 118% less volatile than the broader market. Comparatively, Cipher Pharmaceuticals has a beta of 1.153789, indicating that its share price is 15% more volatile than the broader market.

Cipher Pharmaceuticals has a net margin of 58.81% compared to HLS Therapeutics' net margin of -18.42%. Cipher Pharmaceuticals' return on equity of 22.74% beat HLS Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HLS Therapeutics	-18.42%	-16.54%	-2.89%
Cipher Pharmaceuticals	58.81%	22.74%	7.90%

6.1% of HLS Therapeutics shares are held by institutional investors. Comparatively, 2.3% of Cipher Pharmaceuticals shares are held by institutional investors. 0.4% of HLS Therapeutics shares are held by insiders. Comparatively, 42.0% of Cipher Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

HLS Therapeutics currently has a consensus price target of C$6.00, indicating a potential upside of 50.38%. Cipher Pharmaceuticals has a consensus price target of C$17.00, indicating a potential upside of 20.57%. Given HLS Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe HLS Therapeutics is more favorable than Cipher Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HLS Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, HLS Therapeutics had 1 more articles in the media than Cipher Pharmaceuticals. MarketBeat recorded 3 mentions for HLS Therapeutics and 2 mentions for Cipher Pharmaceuticals. Cipher Pharmaceuticals' average media sentiment score of 1.23 beat HLS Therapeutics' score of 0.51 indicating that Cipher Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HLS Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cipher Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cipher Pharmaceuticals has lower revenue, but higher earnings than HLS Therapeutics. HLS Therapeutics is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HLS Therapeutics	C$55.74M	2.24	-C$15.53M	-C$0.32	N/A
Cipher Pharmaceuticals	C$50.94M	7.03	C$11.41M	C$1.19	11.85

Summary

Cipher Pharmaceuticals beats HLS Therapeutics on 10 of the 16 factors compared between the two stocks.

How does HLS Therapeutics compare to Valens GroWorks?

HLS Therapeutics (TSE:HLS) and Valens GroWorks (CVE:VGW) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

Valens GroWorks has a net margin of 0.00% compared to HLS Therapeutics' net margin of -18.42%. Valens GroWorks' return on equity of 0.00% beat HLS Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HLS Therapeutics	-18.42%	-16.54%	-2.89%
Valens GroWorks	N/A	N/A	N/A

HLS Therapeutics presently has a consensus target price of C$6.00, suggesting a potential upside of 50.38%. Given HLS Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe HLS Therapeutics is more favorable than Valens GroWorks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HLS Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Valens GroWorks	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, HLS Therapeutics had 3 more articles in the media than Valens GroWorks. MarketBeat recorded 3 mentions for HLS Therapeutics and 0 mentions for Valens GroWorks. HLS Therapeutics' average media sentiment score of 0.51 beat Valens GroWorks' score of 0.00 indicating that HLS Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
HLS Therapeutics	Positive
Valens GroWorks	Neutral

6.1% of HLS Therapeutics shares are owned by institutional investors. 0.4% of HLS Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

HLS Therapeutics has higher revenue and earnings than Valens GroWorks. Valens GroWorks is trading at a lower price-to-earnings ratio than HLS Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HLS Therapeutics	C$55.74M	2.24	-C$15.53M	-C$0.32	N/A
Valens GroWorks	C$27.50M	13.96	-C$22.41M	-C$0.18	N/A

Summary

HLS Therapeutics beats Valens GroWorks on 10 of the 15 factors compared between the two stocks.

How does HLS Therapeutics compare to VBI Vaccines?

HLS Therapeutics (TSE:HLS) and VBI Vaccines (TSE:VBV) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.

VBI Vaccines has a net margin of 0.00% compared to HLS Therapeutics' net margin of -18.42%. VBI Vaccines' return on equity of 0.00% beat HLS Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HLS Therapeutics	-18.42%	-16.54%	-2.89%
VBI Vaccines	N/A	N/A	N/A

6.1% of HLS Therapeutics shares are owned by institutional investors. 0.4% of HLS Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, HLS Therapeutics had 3 more articles in the media than VBI Vaccines. MarketBeat recorded 3 mentions for HLS Therapeutics and 0 mentions for VBI Vaccines. HLS Therapeutics' average media sentiment score of 0.51 beat VBI Vaccines' score of 0.00 indicating that HLS Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
HLS Therapeutics	Positive
VBI Vaccines	Neutral

HLS Therapeutics currently has a consensus target price of C$6.00, suggesting a potential upside of 50.38%. Given HLS Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe HLS Therapeutics is more favorable than VBI Vaccines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HLS Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
VBI Vaccines	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

HLS Therapeutics has higher revenue and earnings than VBI Vaccines. HLS Therapeutics is trading at a lower price-to-earnings ratio than VBI Vaccines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HLS Therapeutics	C$55.74M	2.24	-C$15.53M	-C$0.32	N/A
VBI Vaccines	C$3.36M	0.00	-C$62.16M	-C$0.97	N/A

Summary

HLS Therapeutics beats VBI Vaccines on 10 of the 14 factors compared between the two stocks.

How does HLS Therapeutics compare to Supreme Cannabis?

HLS Therapeutics (TSE:HLS) and Supreme Cannabis (TSE:FIRE) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

In the previous week, HLS Therapeutics had 3 more articles in the media than Supreme Cannabis. MarketBeat recorded 3 mentions for HLS Therapeutics and 0 mentions for Supreme Cannabis. HLS Therapeutics' average media sentiment score of 0.51 beat Supreme Cannabis' score of 0.00 indicating that HLS Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
HLS Therapeutics	Positive
Supreme Cannabis	Neutral

Supreme Cannabis has a net margin of 0.00% compared to HLS Therapeutics' net margin of -18.42%. Supreme Cannabis' return on equity of 0.00% beat HLS Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HLS Therapeutics	-18.42%	-16.54%	-2.89%
Supreme Cannabis	N/A	N/A	N/A

HLS Therapeutics has higher revenue and earnings than Supreme Cannabis. HLS Therapeutics is trading at a lower price-to-earnings ratio than Supreme Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HLS Therapeutics	C$55.74M	2.24	-C$15.53M	-C$0.32	N/A
Supreme Cannabis	C$53.29M	0.00	-C$23.65M	-C$0.03	N/A

HLS Therapeutics currently has a consensus price target of C$6.00, suggesting a potential upside of 50.38%. Given HLS Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe HLS Therapeutics is more favorable than Supreme Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HLS Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Supreme Cannabis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

6.1% of HLS Therapeutics shares are held by institutional investors. 0.4% of HLS Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

HLS Therapeutics beats Supreme Cannabis on 9 of the 14 factors compared between the two stocks.

How does HLS Therapeutics compare to Aurora Cannabis?

Aurora Cannabis (TSE:ACB) and HLS Therapeutics (TSE:HLS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership.

Aurora Cannabis has a net margin of -9.53% compared to HLS Therapeutics' net margin of -18.42%. Aurora Cannabis' return on equity of -5.21% beat HLS Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-9.53%	-5.21%	-1.87%
HLS Therapeutics	-18.42%	-16.54%	-2.89%

4.2% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 6.1% of HLS Therapeutics shares are owned by institutional investors. 0.4% of HLS Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Aurora Cannabis has a beta of 0.246838, suggesting that its stock price is 75% less volatile than the broader market. Comparatively, HLS Therapeutics has a beta of -0.178651, suggesting that its stock price is 118% less volatile than the broader market.

Aurora Cannabis presently has a consensus price target of C$7.17, suggesting a potential upside of 42.48%. HLS Therapeutics has a consensus price target of C$6.00, suggesting a potential upside of 50.38%. Given HLS Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe HLS Therapeutics is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
HLS Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

HLS Therapeutics has lower revenue, but higher earnings than Aurora Cannabis. HLS Therapeutics is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	C$314.07M	0.99	-C$44.16M	-C$1.94	N/A
HLS Therapeutics	C$55.74M	2.24	-C$15.53M	-C$0.32	N/A

In the previous week, Aurora Cannabis had 1 more articles in the media than HLS Therapeutics. MarketBeat recorded 4 mentions for Aurora Cannabis and 3 mentions for HLS Therapeutics. Aurora Cannabis' average media sentiment score of 0.77 beat HLS Therapeutics' score of 0.51 indicating that Aurora Cannabis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurora Cannabis	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HLS Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aurora Cannabis beats HLS Therapeutics on 9 of the 16 factors compared between the two stocks.

Get HLS Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HLS vs. The Competition

Export

Metric	HLS Therapeutics	Pharmaceuticals Industry	Healthcare Sector	TSE Exchange
Market Cap	C$124.79M	C$11.72B	C$6.98B	C$12.55B
Dividend Yield	4.30%	2.70%	2.58%	6.20%
P/E Ratio	-12.47	781.44	269.27	30.74
Price / Sales	2.24	748.15	597.31	9.76
Price / Cash	15.22	67.45	70.53	82.29
Price / Book	2.13	10.77	13.07	4.64
Net Income	-C$15.53M	C$2.78B	C$3.45B	C$299.09M
7 Day Performance	-0.99%	-0.17%	0.74%	0.92%
1 Month Performance	-3.62%	0.00%	1.40%	3.90%
1 Year Performance	-21.61%	161.17%	67.03%	36.15%

HLS Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HLS HLS Therapeutics	2.0879 of 5 stars	C$3.91 +1.0%	C$6.00 +53.5%	-24.6%	C$122.29M	C$55.74M	N/A	91	Earnings Report Analyst Upgrade
CPH Cipher Pharmaceuticals	1.9875 of 5 stars	C$17.55 -1.1%	C$17.00 -3.1%	-6.5%	C$445.61M	C$50.94M	14.75	5	Positive News Earnings Report
VGW Valens GroWorks	N/A	C$3.10 +1.6%	N/A	+0.0%	C$383.88M	C$27.50M	N/A	N/A
VBV VBI Vaccines	N/A	N/A	N/A	N/A	C$308.86M	C$3.36M	N/A	22
FIRE Supreme Cannabis	N/A	N/A	N/A	N/A	C$259.40M	C$53.29M	N/A	400

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:HLS) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HLS Therapeutics (HLS) Competitors

HLS vs. CPH, VGW, VBV, FIRE, and ACB

How does HLS Therapeutics compare to Cipher Pharmaceuticals?

Summary

How does HLS Therapeutics compare to Valens GroWorks?

Summary

How does HLS Therapeutics compare to VBI Vaccines?

Summary

How does HLS Therapeutics compare to Supreme Cannabis?

Summary

How does HLS Therapeutics compare to Aurora Cannabis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HLS vs. The Competition

HLS Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HLS Therapeutics (HLS) Competitors

HLS vs. CPH, VGW, VBV, FIRE, and ACB

How does HLS Therapeutics compare to Cipher Pharmaceuticals?

Which has more risk & volatility, HLS or CPH?

Is HLS or CPH more profitable?

Do insiders & institutionals believe in HLS or CPH?

Do analysts rate HLS or CPH?

Does the media favor HLS or CPH?

Which has stronger valuation & earnings, HLS or CPH?

Summary

How does HLS Therapeutics compare to Valens GroWorks?

Is HLS or VGW more profitable?

Do analysts prefer HLS or VGW?

Does the media favor HLS or VGW?

Do institutionals and insiders hold more shares of HLS or VGW?

Which has higher valuation and earnings, HLS or VGW?

Summary

How does HLS Therapeutics compare to VBI Vaccines?

Is HLS or VBV more profitable?

Do institutionals & insiders hold more shares of HLS or VBV?

Does the media refer more to HLS or VBV?

Do analysts prefer HLS or VBV?

Which has higher valuation & earnings, HLS or VBV?

Summary

How does HLS Therapeutics compare to Supreme Cannabis?

Does the media refer more to HLS or FIRE?

Is HLS or FIRE more profitable?

Which has better valuation & earnings, HLS or FIRE?

Do analysts prefer HLS or FIRE?

Do insiders and institutionals have more ownership in HLS or FIRE?

Summary

How does HLS Therapeutics compare to Aurora Cannabis?

Is ACB or HLS more profitable?

Do insiders & institutionals hold more shares of ACB or HLS?

Which has more risk and volatility, ACB or HLS?

Do analysts recommend ACB or HLS?

Which has higher earnings & valuation, ACB or HLS?

Does the media refer more to ACB or HLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HLS vs. The Competition

HLS Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools